Immunic

Immunic is a clinical-stage biopharmaceutical company developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. 

arrow miss target fail attempt try
Biotech

Immunic MS asset misses primary goal of midstage trial

IMU-838 showed only “modest benefit” over placebo at improving the yearly rate of percent brain volume change in patients with progressive MS.
Darren Incorvaia Apr 30, 2025 3:05pm
Alzheimers brain

Immunic's investors appeased by biomarker data from MS trial

Oct 10, 2023 9:35am
change direction new plan alter arrows move reprioritize

Immunic punts psoriasis and prostate programs to narrow focus

Apr 5, 2023 9:05am
Nasdaq

Dreaded 'high placebo rate' hits Immunic's psoriasis trial

Oct 21, 2022 8:00am
money and shares declining

Immunic regains some momentum with multiple sclerosis update

Jun 15, 2022 9:35am
stock market down crash fail shares

Immunic shifts back to multiple sclerosis after UC fail

Jun 6, 2022 6:45am